Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Theo Rispens

Showing results (131-140 of 304) with videos related to

Pageof 31
Sort By:
Annals of the Rheumatic Diseases|April 13, 2023
Rheumatoid factor autoantibody repertoire profiling reveals distinct binding epitopes in health and autoimmunityNienke Oskam, Pleuni Ooijevaar-De Heer, Dorien Kos, et al.
Journal of Neurology|April 21, 2019
Anti-natalizumab antibodies during 8 years of natalizumab treatment: effect on natalizumab concentration and α4-integrin receptor saturationZoé L E van Kempen, Johannis A van Rossum, Djoeke Doesburg, et al.
Therapeutic Drug Monitoring|November 7, 2024
Precision Dosing of Intravenous Tocilizumab: Development of Pharmacokinetic Model-Derived Tapering Strategies for Patients With Rheumatoid ArthritisFemke Hooijberg, Stefan P H van den Berg, Zohra Layegh, et al.
Molecular & Cellular Proteomics : MCP|March 12, 2015
Hinge-Region O-Glycosylation of Human Immunoglobulin G3 (IgG3)Rosina Plomp, Gillian Dekkers, Yoann Rombouts, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 15, 2022
At Critically Low Antigen Densities, IgM Hexamers Outcompete Both IgM Pentamers and IgG1 for Human Complement Deposition and Complement-Dependent CytotoxicityNienke Oskam, Pleuni Ooijevaar-de Heer, Ninotska I L Derksen, et al.
Annals of the Rheumatic Diseases|April 30, 2017
Infusion reactions during infliximab treatment are not associated with IgE anti-infliximab antibodiesKarin A van Schie, Pleuni Ooijevaar-De Heer, Simone Kruithof, et al.
Pharmaceutics|May 27, 2023
Optimization of a Quantitative Anti-Drug Antibodies against Infliximab Assay with the Liquid Chromatography-Tandem Mass Spectrometry: A Method Validation Study and Future PerspectivesErin H Smeijsters, Kim C M van der Elst, Amy Visch, et al.
Annals of the Rheumatic Diseases|September 28, 2014
Golimumab trough levels, antidrug antibodies and clinical response in patients with rheumatoid arthritis treated in daily clinical practiceEva L Kneepkens, Chamaida Plasencia, Charlotte Lm Krieckaert, et al.
Journal of Immunology Research|March 11, 2026
Combining Activation-Induced Markers With PD-L1 Selectively Enhances Detection of Antigen-Specific T Cells in Virus-Infected IndividualsChristine Kreher, Laura Y L Kummer, Maryse Tempert, et al.
Frontiers in Immunology|October 2, 2019
<i>N</i>-Glycosylation Site Analysis of Citrullinated Antigen-Specific B-Cell Receptors Indicates Alternative Selection Pathways During Autoreactive B-Cell DevelopmentRochelle D Vergroesen, Linda M Slot, Barbera D C van Schaik, et al.
Pageof 31

Showing results (131-140 of 304) with videos related to

Sort By:
Pageof 31
Annals of the Rheumatic Diseases|April 13, 2023
Rheumatoid factor autoantibody repertoire profiling reveals distinct binding epitopes in health and autoimmunityNienke Oskam, Pleuni Ooijevaar-De Heer, Dorien Kos, et al.
Journal of Neurology|April 21, 2019
Anti-natalizumab antibodies during 8 years of natalizumab treatment: effect on natalizumab concentration and α4-integrin receptor saturationZoé L E van Kempen, Johannis A van Rossum, Djoeke Doesburg, et al.
Therapeutic Drug Monitoring|November 7, 2024
Precision Dosing of Intravenous Tocilizumab: Development of Pharmacokinetic Model-Derived Tapering Strategies for Patients With Rheumatoid ArthritisFemke Hooijberg, Stefan P H van den Berg, Zohra Layegh, et al.
Molecular & Cellular Proteomics : MCP|March 12, 2015
Hinge-Region O-Glycosylation of Human Immunoglobulin G3 (IgG3)Rosina Plomp, Gillian Dekkers, Yoann Rombouts, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 15, 2022
At Critically Low Antigen Densities, IgM Hexamers Outcompete Both IgM Pentamers and IgG1 for Human Complement Deposition and Complement-Dependent CytotoxicityNienke Oskam, Pleuni Ooijevaar-de Heer, Ninotska I L Derksen, et al.
Annals of the Rheumatic Diseases|April 30, 2017
Infusion reactions during infliximab treatment are not associated with IgE anti-infliximab antibodiesKarin A van Schie, Pleuni Ooijevaar-De Heer, Simone Kruithof, et al.
Pharmaceutics|May 27, 2023
Optimization of a Quantitative Anti-Drug Antibodies against Infliximab Assay with the Liquid Chromatography-Tandem Mass Spectrometry: A Method Validation Study and Future PerspectivesErin H Smeijsters, Kim C M van der Elst, Amy Visch, et al.
Annals of the Rheumatic Diseases|September 28, 2014
Golimumab trough levels, antidrug antibodies and clinical response in patients with rheumatoid arthritis treated in daily clinical practiceEva L Kneepkens, Chamaida Plasencia, Charlotte Lm Krieckaert, et al.
Journal of Immunology Research|March 11, 2026
Combining Activation-Induced Markers With PD-L1 Selectively Enhances Detection of Antigen-Specific T Cells in Virus-Infected IndividualsChristine Kreher, Laura Y L Kummer, Maryse Tempert, et al.
Frontiers in Immunology|October 2, 2019
<i>N</i>-Glycosylation Site Analysis of Citrullinated Antigen-Specific B-Cell Receptors Indicates Alternative Selection Pathways During Autoreactive B-Cell DevelopmentRochelle D Vergroesen, Linda M Slot, Barbera D C van Schaik, et al.
Pageof 31